Section Editor Prof. Dr. Jan C. Simon, Leipzig
Nail psoriasis – a treatment challenge
Version of Record online: 20 FEB 2013
© The Authors | Journal compilation © Blackwell Verlag GmbH, Berlin
JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Volume 11, Issue 3, pages 203–220, March 2013
How to Cite
Radtke, M. A., Beikert, F. C. and Augustin, M. (2013), Nail psoriasis – a treatment challenge. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 11: 203–220. doi: 10.1111/ddg.12054
Conflicts of interest Support for clinical studies, research on health services, and guest speaker fees provided by Abbott, Pfizer, MSD, Janssen, Biogen idec, Leo Pharma.
A 2010 study published in Germany on 3,531 psoriasis patients reported that 41% had nail involvement.
Other sources report a lifetime incidence of nail psoriasis among psoriasis patients of 80–90%.
Nail pitting occurs as a result of abnormal keratinization with severe parakeratosis and an accumulation of nuclear remnants on the surface of the nail plate.
Psoriatic ìoil spotsî caused by parakeratotic changes in the nail bed.
Subungual hyperkeratosis is hyperproliferation of the nail bed due to a psoriatic lesion at the affected site.
HLA-CW*0602 allele has the strongest association to the disease.
Systemic therapy should also be favored if there is concomitant joint involvement (psoriatic arthritis).
The fundamental challenge for topical therapy arises from the fact that the antipsoriatic agents can only very slowly penetrate into the nail plate – or not at all.
Intralesional steroid injections are a traditional form of treatment which offer safe and effective treatment of nail psoriasis, especially if the nail matrix is involved.
Fumaric acid esters
Measures to protect the nails can be an important part of treatment success
- Issue online: 20 FEB 2013
- Version of Record online: 20 FEB 2013
- Submitted: 12.6.2012 Accepted: 10.1.2013
- 7Diagnosis and management of nail psoriasis. Actas Dermosifiliogr 2008; 99: 34–43., .
- 9Treatment options for nail psoriasis. Expert Rev Dermatol 2008; 3: 339–344., , , , .
- 33For the NAPPA task force group: Conception, development and validation of NAPPA, a novel questionnaire for the assessment of patient-reported outcomes in nail psoriasis. Submitted 2013., , , , .
- 35Nail psoriasis as a severity indicator: results from the PsoReal study. Patient Related Outcomes Measures 2011; 2: 1–6., , , , , .
- 44Baran R, Dawber RPR (eds). Diseases of the Nail and Their Management. Oxford , Blackwell Science, 1984.
- 49Topical calcipotriol therapy in nail psoriasis: a study of 24 cases. Dermatol Online J 2005; 11: 5., , , .
- 52Nail psoriasis treated with calcipotriol (MC903): an open study. J Dermatol Treat 1994; 5: 149–150., , , .
- 62S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges 2012; 10: Suppl 2: S1–95., , , , , , , , , , , , , , , , , , , , , .
- 66A phase IIIb, multicenter, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calicpotriol/betamethasone topical treatment in patients with moderate to severe psoriasis:the BELIEVE study. Br J Dermatol 2010; 163: 402–411., , , , , , , , , , , .
- 71Improvement in nail psoriasis with ustekinumab, a new anti-IL-12/23 P40 monoclonal antibody: results from a phase 3 trial (PHOENIX 1). 2008 EADV Abstract FP1007..